½ÃÀ庸°í¼­
»óǰÄÚµå
1363049

À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ä¡·áº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 58¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2023³âºÎÅÍ 2030³â±îÁö 7.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯Àü¼º Ç÷°ü¼º ºÎÁ¾(HAE)¿¡ ´ëÇÑ È¯ÀÚ ¹× ÀÇ·á ¼­ºñ½º Á¦°øÀÚ »çÀÌ¿¡¼­ À¯Àü¼º Ç÷°ü¼º ºÎÁ¾(HAE)¿¡ ´ëÇÑ ÀÎÁöµµ¸¦ ³ôÀ̱â À§ÇÑ ±¹Á¦ ȯÀÚ ´ÜüÀÇ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡´Â ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡´Â ÃËÁøÁ¦°¡ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

HAE International(HAEi)¿¡ ¼Ò¼ÓµÈ ȯÀÚ Áö¿ø ´ÜüµéÀº À¯Àü¼º Ç÷°ü¼º ºÎÁ¾¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇØ Àμ⹰°ú ¼Ò¼È ¹Ìµð¾î¸¦ ÅëÇÑ Ä·ÆäÀο¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, HAEi´Â ȯÀÚµéÀÇ ÀÎ½Ä ¼öÁØÀ» ³ôÀ̱â À§ÇØ °¡Á· °Ë»ç µµ±¸¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. CSL Limited, Pharming Group N.V., Shire Plc¿Í °°Àº Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéµµ À¯Àü¼º Ç÷°ü¼º ºÎÁ¾ÀÇ È¿°úÀûÀÎ Áø´Ü °úÁ¤°ú Ä¡·á¹ýÀ» È®¸³Çϱâ À§ÇØ À¯Àü¼º Ç÷°ü¼º ºÎÁ¾ÀÇ È¿°úÀûÀÎ Áø´Ü ¹× Ä¡·á¹ý °³¹ß¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. À¯Àü¼º Ç÷°ü¼º ºÎÁ¾ÀÇ È¿°úÀûÀÎ Áø´Ü °úÁ¤°ú Ä¡·á¹ýÀ» È®¸³Çϱâ À§ÇØ À¯Àü¼º Ç÷°ü¼º ºÎÁ¾ Ä¿¹Â´ÏƼ¿Í Çù·ÂÇϰí ÀÖ½À´Ï´Ù.

À¯Àü¼º Ç÷°ü¼º ºÎÁ¾ÀÇ ¹ßÀÛÀ» °ü¸®Çϱâ À§ÇÑ »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ Àü ¼¼°è ¿©·¯ ±¹°¡ÀÇ ´ëÇеéÀÌ ¼­·Î Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2018³â¿¡´Â À¯·´, È£ÁÖ, ij³ª´ÙÀÇ 26°³ ´ëÇÐÀÌ ÀÌ ÁúȯÀÇ ¿¹¹æÀ» À§ÇÑ »õ·Î¿î °æ±¸¿ë Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇØ ±¹Á¦ °øµ¿¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù.

°¢±¹ÀÌ »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚÀÇ Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇØ ½ÃÇàÇϰí ÀÖ´Â Á¶Ä¡µéÀº HAE¿¡ ´ëÇÑ ½Å¼ÓÇÑ ¾à¹° ½É»ç ¹× ½ÂÀÎÀ» ÃËÁøÇϱâ À§ÇÑ ±ÔÁ¦ °¡À̵å¶óÀÎÀÇ °³Á¤°ú ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2018³â 7¿ù Áß±¹ ±¹°¡À§»ý°Ç°­À§¿øÈ¸(NHC)¿Í ±¹°¡¾àǰ°¨µ¶°ü¸®±¹(SDA)Àº ÇöÀç ±¹³»¿¡¼­ Ä¡·áÁ¦°¡ Á¦°øµÇÁö ¾Ê´Â Èñ±ÍÁúȯ Ä¡·áÁ¦¿¡ ´ëÇØ Á¦¾à»ç°¡ ½Å¾à½ÂÀνÅû(NDA)À» ÇÒ ¼ö ÀÖµµ·Ï Çã¿ëÇß½À´Ï´Ù. À̹ø °áÁ¤À¸·Î Á¦¾à»çµéÀº ½Å¾à ½ÂÀÎ ½Åû ½Ã Áß±¹ ¿ÜÀÇ ÀÓ»ó½ÃÇè µ¥ÀÌÅ͸¦ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÆ½À´Ï´Ù.

À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • C1-¿¡½ºÅ×¶ó¾ÆÁ¦ ¾ïÁ¦Á¦ ºÎ¹®Àº HAEÀÇ ¿Âµð¸Çµå Ä¡·á ¹× ¿¹¹æ Ä¡·á¿¡¼­ Á¦Ç°ÀÇ ³ôÀº »ç¿ë·ü·Î ÀÎÇØ 2022³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ¿Âµð¸Çµå Ä¡·á´Â ½ÃÀå¿¡¼­ ¾ÐµµÀûÀÎ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »õ·Î¿î Áö¿ª¿¡¼­ÀÇ Á¦Ç° Ãâ½Ã°¡ ÀÌ ºÎ¹®ÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â 2022³â ¸ÅÃâ·Î Àüü À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ ÁúȯÀÇ »ç·Ê ¼ö Áõ°¡, À¯¸®ÇÑ Á¤ºÎ ÇÁ·Î±×·¥, ȯÀÚµéÀÇ ÀÎ½Ä ¼öÁØ Çâ»ó, °íµµ·Î Àü¹®È­µÈ ÀÇ·áÁøÀÇ Á¸Àç´Â ÀÌ Áö¿ª ½ÃÀåÀÇ ÁÖ¿ä Á¡À¯À²¿¡ ±â¿©ÇÏ´Â ¿äÀÎÀÔ´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±°ú ³ôÀº ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÀÌ ÁúȯÀÇ Ä¡·á¸¦ À§ÇÑ »õ·Î¿î Ä¡·á¹ýÀÇ Ãâ½Ã´Â ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
  • ÁÖ¿ä ±â¾÷À¸·Î´Â Ionis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire plc, Adverum Biotechnologies, Inc., Attune Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : Ä¡·áº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
  • À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • C1-¿¡½ºÅ×¶óÁ¦ ¾ïÁ¦Á¦
  • ºê·¡µðŰ´Ñ B2 ¼ö¿ëü ±æÇ×Á¦
  • Ä®¸®Å©·¹ÀÎ ¾ïÁ¦Á¦
  • ±âŸ

Á¦5Àå À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
  • À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • ¿¹¹æ
  • ¿Âµð¸Çµå

Á¦6Àå À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : Åõ¿© °æ·Îº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
  • À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • Á¤¸Æ³»
  • ÇÇÇÏ
  • °æ±¸

Á¦7Àå À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° Àü¸Á
  • Áö¿ªº° À¯Àü¼º Ç÷°üºÎÁ¾ Ä¡·áÁ¦ ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
  • ºÏ¹Ì
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï »óȲ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
    • BioCryst Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals
    • CSL
    • Attune Pharmaceuticals
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Pharming
ksm 23.11.01

Hereditary Angioedema Therapeutics Market Growth & Trends:

The global hereditary angioedema therapeutic market size is expected to reach USD 5.8 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a 7.4% CAGR from 2023 to 2030. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China's National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Hereditary Angioedema Therapeutics Market Report Highlights:

  • The C1-esterase inhibitor segment held the largest share in 2022 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE
  • On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment
  • North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2022. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market
  • Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region
  • Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. End-use
    • 1.1.3. Route of administration
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Angioedema Therapeutic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Hereditary Angioedema Therapeutic Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Hereditary Angioedema Therapeutic Market: Treatment Estimates & Trend Analysis

  • 4.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 4.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. C1-esterase Inhibitor
    • 4.3.1. C1-esterase inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Bradykinin B2 Receptor Antagonist
    • 4.4.1. Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Kallikrein Inhibitor
    • 4.5.1. Kallikrein inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Hereditary Angioedema Therapeutic Market: End-use Estimates & Trend Analysis

  • 5.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 5.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Prophylaxis
    • 5.3.1. Silicon market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. On-demand
    • 5.4.1. Metal market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Hereditary Angioedema Therapeutic Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 6.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Intravenous
    • 6.3.1. Intravenous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.4. Subcutaneous
    • 6.4.1. Subcutaneous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 7. Hereditary Angioedema Therapeutic Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Hereditary Angioedema Therapeutic Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. BioCryst Pharmaceuticals, Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Ionis Pharmaceuticals
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. CSL
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Attune Pharmaceuticals
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Adverum Biotechnologies, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. KalVista Pharmaceuticals, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Takeda Pharmaceutical Company Limited
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Pharming
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiative
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦